A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study.
Chronic disease management
Healthcare quality improvement
Sacubitril-valsartan
Systematic implementation
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
06
04
2020
accepted:
11
08
2020
pubmed:
21
8
2020
medline:
23
9
2021
entrez:
22
8
2020
Statut:
ppublish
Résumé
To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. The systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records/databases/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care. The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient's confidence in healthcare.
Identifiants
pubmed: 32820363
doi: 10.1007/s00228-020-02979-w
pii: 10.1007/s00228-020-02979-w
pmc: PMC7782406
doi:
Substances chimiques
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Biphenyl Compounds
0
Drug Combinations
0
Valsartan
80M03YXJ7I
sacubitril and valsartan sodium hydrate drug combination
WB8FT61183
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-131Subventions
Organisme : The Heart Foundation of Northern Sweden
ID : -
Organisme : The 1,6 Million Club
ID : -
Références
Lavoie KL, Rash JA, Campbell TS (2017) Changing provider behavior in the context of chronic disease management: focus on clinical inertia. Annu Rev Pharmacol Toxicol 57:263–283. https://doi.org/10.1146/annurev-pharmtox-010716-104952
doi: 10.1146/annurev-pharmtox-010716-104952
pubmed: 27618738
Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM (2018) Adoption of sacubitril/valsartan for the management of patients with heart failure. Circ Heart Fail 11:e004302. https://doi.org/10.1161/circheartfailure.117.004302
doi: 10.1161/circheartfailure.117.004302
pubmed: 29453287
pmcid: 5820776
Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O’Brien EC (2017) Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the Guidelines-Heart Failure (GWTG-HF). JACC Heart Fail 5:305–309. https://doi.org/10.1016/j.jchf.2016.12.018
doi: 10.1016/j.jchf.2016.12.018
pubmed: 28359417
Schneeweiss S (2007) Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 82:143–156. https://doi.org/10.1038/sj.clpt.6100249
doi: 10.1038/sj.clpt.6100249
pubmed: 17554243
Nakano A, Egstrup K, Svendsen ML, Schjødt I, Jakobsen L, Mehnert F, Johnsen SP (2016) Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark. Age Ageing 45:635–642. https://doi.org/10.1093/ageing/afw119
doi: 10.1093/ageing/afw119
pubmed: 27496924
Jonsson A, Norberg H, Bergdahl E, Lindmark K (2018) Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. Cardiovasc Ther 36:e12459. https://doi.org/10.1111/1755-5922.12459
doi: 10.1111/1755-5922.12459
pubmed: 30019390
pmcid: 6175311
Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, Lund LH (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20:1326–1334. https://doi.org/10.1002/ejhf.1182
doi: 10.1002/ejhf.1182
pubmed: 29578280
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128
doi: 10.1093/eurheartj/ehw128
pubmed: 27206819
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:e137–e161. https://doi.org/10.1161/cir.0000000000000509
doi: 10.1161/cir.0000000000000509
pubmed: 28455343
McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004. https://doi.org/10.1056/NEJMoa1409077
doi: 10.1056/NEJMoa1409077
pubmed: 25176015
Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105–112. https://doi.org/10.1016/j.nedt.2003.10.001
doi: 10.1016/j.nedt.2003.10.001
National Board of Health and Welfare. Drug statistics [internet]. 2016 Stockholm. [cited 3 Aug 2020]; Available from: https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/lakemedel/ .
Lenzen MJ, Rosengren A, Scholte OP, Reimer WJ et al (2008) Management of patients with heart failure in clinical practice: differences between men and women. Heart 94:e10. https://doi.org/10.1136/hrt.2006.099523
doi: 10.1136/hrt.2006.099523
pubmed: 17575332
Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GM (2017) Under-representation of elderly and women in clinical trials. Int J Cardiol 232:216–221. https://doi.org/10.1016/j.ijcard.2017.01.018
doi: 10.1016/j.ijcard.2017.01.018
pubmed: 28111054
Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld JA, O’Connor CM, Butler J (2018) Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol 3:1011–1019. https://doi.org/10.1001/jamacardio.2018.2559
doi: 10.1001/jamacardio.2018.2559
pubmed: 30140928
Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, Elahi M, Temple RJ, Woodcock J (2018) Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol 71:1960–1969. https://doi.org/10.1016/j.jacc.2018.02.070
doi: 10.1016/j.jacc.2018.02.070
pubmed: 29724348
Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK (2010) Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 3:135–142. https://doi.org/10.1161/circoutcomes.110.868307
doi: 10.1161/circoutcomes.110.868307
pubmed: 20160159